Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 8/2016

01-08-2016 | Original Article

Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in France

Authors: Vincent Launay-Vacher, Nicolas Janus, Gilbert Deray, Florian Scotté

Published in: Supportive Care in Cancer | Issue 8/2016

Login to get access

Abstract

Purpose

The aim of the LIDOanemia surveys was to assess how anemia in cancer patients is managed by oncologists and hematologists according to the key messages of the EORTC guidelines.

Methods

LIDO 1 and LIDO 2 (Leaning upon International Directives for Optimization: Anemia) were declarative web-based surveys conducted in France. LIDO 1 specifically focused on clinical features triggering the decision to treat anemia, biological indicators of anemia, the hemoglobin (Hb) threshold for initiating treatment and blood transfusion, and the Hb treatment target. In LIDO 2, participants were presented the main messages of the EORTC guidelines and were asked four questions to assess the impact of the guideline’s broadcast on their practice.

Results

A total of 133 and 319 physicians took part in the LIDO 1 and 2 surveys, respectively. The majority were oncologists (65 and 61 %, respectively). Responses from LIDO 1 showed practice habits that differed from those recommended in the EORTC guidelines. However, LIDO 2 showed that an average of 18 % of the participating physicians were willing to amend their clinical practice after receiving a summary of the EORTC recommendations for anemia management.

Conclusion

These findings raise the questions of how often and how to most effectively disseminate key guideline messages. With the best interests of patients in mind, the ultimate objective is to improve the understanding of consensus recommendations and to close the gap between them and actual clinical practice.
Appendix
Available only for authorised users
Literature
1.
Ludwig H, Muldur E, Endler G, Hubl W (2013) Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 24(7):1886–1892CrossRefPubMedPubMedCentral
2.
Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91(12):2214–2221CrossRefPubMed
3.
Harper P, Littlewood T (2005) Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology 69(Suppl 2):2–7CrossRefPubMed
4.
Sabbatini P (2000) Contribution of anemia to fatigue in the cancer patient. Oncology (Williston Park) 14(11a):69–71
5.
Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40(15):2293–2306CrossRefPubMed
6.
Guardiola E, Morschhauser F, Zambrowski J-J, Antoine E-C (2007) Prise en charge de l’anémie chez les patients présentant une pathologie maligne: résultats de l’étude. F-ACT (French Anaemia Cancer Treatment) Bull Cancer 94(10):907–914PubMed
7.
Lai-Tiong F, Brami C, Dubroeucq O, Scotte F, Cure H, Jovenin N (2015) Management of anemia and iron deficiency in a cancer center in France. Support Care Cancer Aug 8 [Epub ahead of print].
8.
Spielmann M, Luporsi E, Ray-Coquard I, de Botton S, Azria D, Lasocki S, et al. (2012) Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: the AnemOnHe study. Eur J Cancer 48(1):101–107CrossRefPubMed
9.
Schneider M (2005) Fréquence de l’anémie chez les patients français atteints de tumeurs solides ou d’hémopathies malignes: résultats de l’«European Cancer Anaemia Survey (ECAS)». Oncologie 7(5):397–402CrossRef
10.
Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl 3):33–36CrossRefPubMed
11.
Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43(2):258–270CrossRefPubMed
12.
Schrijvers D, De Samblanx H, Roila F, ESMO Guidelines Working Group (2010) Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 21(Suppl 5):v244–v247CrossRefPubMed
13.
Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40(15):2201–2216CrossRefPubMed
14.
Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D, et al. (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986–1992CrossRefPubMed
15.
Grunberg S, Clark-Snow RA, Koeller J (2010) Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. Proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting. Support Care Cancer 18(suppl 1):S1–10CrossRefPubMed
16.
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(suppl 5):v232–v243CrossRefPubMed
17.
Bohlius J, Tonia T, Nuesch E, Juni P, Fey MF, Egger M, et al. (2014) Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Br J Cancer 111(1):33–45CrossRefPubMedPubMedCentral
18.
Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B (2012) Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 106(7):1249–1258CrossRefPubMedPubMedCentral
19.
Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, et al. (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34(3 Suppl 2):4–12PubMed
20.
Campos MP, Hassan BJ, Riechelmann R, Del Giglio A (2011) Cancer-related fatigue: a practical review. Ann Oncol 22(6):1273–1279CrossRefPubMed
21.
Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, et al. (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5(5):353–360CrossRefPubMed
22.
Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N (2000) Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum Ann Oncol 11(8):971–975PubMed
23.
24.
Gascón P, Rodriguez CA, Valentin V, Mata JG, Carulla J, Cassinello J, et al. (2013) Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study. Support Care Cancer 21(11):3039–3049CrossRefPubMedPubMedCentral
25.
Sabbatini P (2000) The relationship between anemia and quality of life in cancer patients. Oncologist 5(Suppl 2):19–23CrossRef
26.
Cella D (2002) The effects of anemia and anemia treatment on the quality of life of people with cancer. Oncology (Williston Park) 16(9 Suppl 10):125–132
27.
Lind M, Vernon C, Cruickshank D, Wilkinson P, Littlewood T, Stuart N, et al. (2002) The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 86(8):1243–1249CrossRefPubMedPubMedCentral
Metadata
Title
Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in France
Authors
Vincent Launay-Vacher
Nicolas Janus
Gilbert Deray
Florian Scotté
Publication date
01-08-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 8/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3162-x

Other articles of this Issue 8/2016

Supportive Care in Cancer 8/2016 Go to the issue

Original Article

Implementation of a mobile inpatient quality of life (QoL) assessment for oncology nursing

Review Article

Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review

Review Article

The lived experience of fatigue in children and adolescents with cancer: a systematic review

Original Article

The trajectory of neurotoxic side effects’ impact on daily life: a qualitative study

Erratum

Erratum to: The well-being of children impacted by a parent with cancer: an integrative review

Erratum

Erratum to: Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits